A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

NCT02700022 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Burkitt Lymphoma

Interventions

DRUG: Alisertib

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]